Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Till

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Blood|April 29, 2024
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantationElizabeth F Krakow, Michelle Brault, Corinne Summers, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Transplantation and Cellular Therapy|September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Blood Advances|March 19, 2026
Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin LymphomaGrace Baek, Gaurav Varma, Samuel Yamshon, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Blood|April 29, 2024
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantationElizabeth F Krakow, Michelle Brault, Corinne Summers, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Transplantation and Cellular Therapy|September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Blood Advances|March 19, 2026
Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin LymphomaGrace Baek, Gaurav Varma, Samuel Yamshon, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Pageof 12